Carl Harald Janson
Directeur/Bestuurslid bij Aprea Personal AB
Profiel
Carl Harald Ramon Janson is currently a Director at KCIF Fund Management AB, Aprea Personal AB, and the owner of Carl Harald Janson Förvaltning AB.
He previously held positions such as Chief Executive Officer & Director at Akinion Pharmaceuticals AB, Chief Executive Officer at KDev Oncology AB, and Director at Oncopeptides AB, Astra Arcus AB, Aprea Therapeutics AB, Axelar AB, ClanoTech AB, and Limone AB.
He was also a Lead Manager-Investment at International Biotechnology Trust Plc from 2013 to 2021, a Portfolio Manager at Carnegie Fond AB from 2004 to 2007, and a Senior Portfolio Manager & Principal Fund Manager at Carnegie Investment Bank AB.
Additionally, he was an Investment Manager at Karolinska Development AB (Private Equity) from 2008 to 2011, a Managing Partner at Zaramant Fonder AB from 2007 to 2008, and a Vice President-Portfolio Management at Karolinska Development AB.
He holds a doctorate degree from Karolinska Institutet, which he received in 1990.
Actieve functies van Carl Harald Janson
| Bedrijven | Functie | Begin |
|---|---|---|
| Aprea Personal AB | Directeur/Bestuurslid | 21-04-2011 |
| KCIF Fund Management AB | Directeur/Bestuurslid | 21-04-2011 |
| Carl Harald Janson Förvaltning AB | Corporate Officer/Principal | 21-04-2011 |
Eerdere bekende functies van Carl Harald Janson
| Bedrijven | Functie | Einde |
|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | Chief Investment Officer | 15-03-2021 |
SV Health Managers LLP
 SV Health Managers LLP Investment ManagersFinance SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest. | Portefeuillebeheerder-Aandelen | 01-02-2021 |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Private Equity Investor | 31-12-2011 |
| Zaramant Fonder AB | Chief Investment Officer | 01-01-2008 |
Carnegie Fond AB
 Carnegie Fond AB Investment ManagersFinance Carnegie Fond AB (CF) is a wholly-owned subsidiary of Carnegie Investment Bank AB, in turn a wholly-owned subsidiary of the Stockholm-based financial group D.Carnegie & Co AB (ST: CAR). CF is located in Stockholm. The firm is a fund management specialist. They manage mutual funds for the parent group and sub-advise portfolios for third-parties. CF cooperates closely with their fellow subsidiary Carnegie Asset Management AB. | Portefeuillebeheerder-Aandelen | 01-01-2007 |
Opleiding van Carl Harald Janson
| Karolinska Institutet | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ONCOPEPTIDES AB | Health Technology |
| KAROLINSKA DEVELOPMENT AB | Finance |
| Bedrijven in privébezit | 16 |
|---|---|
International Biotechnology Trust Plc
 International Biotechnology Trust Plc Investment Trusts/Mutual FundsMiscellaneous International Biotechnology Trust Plc is a closed end investment trust company, which invests in the development staged biotechnology and other life sciences industries. The company was founded on January 1, 1994 and is headquartered in London, the United Kingdom. | Miscellaneous |
Carnegie Fond AB
Carnegie Fond AB Investment ManagersFinance Carnegie Fond AB (CF) is a wholly-owned subsidiary of Carnegie Investment Bank AB, in turn a wholly-owned subsidiary of the Stockholm-based financial group D.Carnegie & Co AB (ST: CAR). CF is located in Stockholm. The firm is a fund management specialist. They manage mutual funds for the parent group and sub-advise portfolios for third-parties. CF cooperates closely with their fellow subsidiary Carnegie Asset Management AB. | Finance |
Carnegie Investment Bank AB
 Carnegie Investment Bank AB Investment Banks/BrokersFinance Carnegie Investment Bank AB is the broker/delear subsidiary of Carnegie Holding AB in Sweden. Headquartered in Stockholm, the firm was founded in 1803 and offers institutional clients several services within research, equity sales and equity capital market transactions (ECM). The Fixed Income unit offers bond research and sales. Carnegie Investment Bank’s research and equity sales enjoy a global position in Nordic equities. | Finance |
Karolinska Development AB (Private Equity)
Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | Finance |
| Zaramant Fonder AB | Finance |
| Astra Arcus AB | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Axelar AB
 Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
SV Health Managers LLP
SV Health Managers LLP Investment ManagersFinance SV Health Managers LLP (SVHM) is the investment management subsidiary of SV Life Sciences Advisers LLP in the UK. Established in 2005, the firm was formerly known as SV Life Sciences Managers LLP and changed their name to SV Health Managers LLP in 2017. Based in London, the firm manages the International Biotechnology Trust plc (LSE: IBT), an investment trust vehicle listed on the London Stock Exchange into which corporate and private investors may invest. | Finance |
| KCIF Fund Management AB | |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Health Technology |
Limone AB
 Limone AB Pharmaceuticals: MajorHealth Technology Limone is developing new treatments for cancer. The target is the protein LL37 recently reported to act as a growth factor for cancer cells in various cancer indications. Limone has a patent estate covering LL37 and is actively looking for a partner to develop this therapeutic concept. | Health Technology |
| Aprea Personal AB | |
| Carl Harald Janson Förvaltning AB | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Commercial Services |
